Ocular Therapeutix
OCUL
216 hedge funds and large institutions have $2.2B invested in Ocular Therapeutix in 2025 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 72 increasing their positions, 58 reducing their positions, and 18 closing their positions.
183% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 18
105% more call options, than puts
Call options by funds: $22M | Put options by funds: $10.7M
51% more capital invested
Capital invested by funds: $1.45B → $2.2B (+$746M)
24% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 58
16% more funds holding
Funds holding: 186 → 216 (+30)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
9.56% more ownership
Funds ownership: 98.59% → 108.15% (+9.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$146M |
| 2 |
Millennium Management
New York
|
+$44.7M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$39M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$34.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$28.2M |
| 2 |
SR
Summer Road
West Palm Beach,
Florida
|
-$15.6M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.7M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$10.9M |
| 5 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$9.79M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
YIH
226
Y-Intercept (HK)
Hong Kong
| – | -$342K | -36,815 | Closed |
|
|
LSA
227
Leonteq Securities AG
Zurich,
Switzerland
| – | -$232K | -25,000 | Closed |
|
228
Group One Trading
Chicago,
Illinois
| – | -$143K | -11,950 | Closed |
|
|
QC
229
Quantessence Capital
New York
| – | -$106K | -11,467 | Closed |
|
|
AAS
230
Ameritas Advisory Services
Lincoln,
Nebraska
| – | -$2.7K | -291 | Closed |
|
|
AAP
231
Arax Advisory Partners
Denver,
Colorado
| – | -$808 | -87 | Closed |
|
232
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$19 | -2 | Closed |
|
|
TPWA
233
Twin Peaks Wealth Advisors
Burlingame,
California
| – | -$25 | -2 | Closed |
|
OCUL Hedge Fund Activity: Q3 2025 in Review
216 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q3 2025, worth a combined $2.2B — up 51% from $1.45B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new OCUL positions and 18 closed out — a net gain of 33 holders — while 72 added to existing stakes and 58 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $146M. The largest seller was Deep Track Capital, cutting an estimated $28.2M.
- 216 institutional investors held Ocular Therapeutix (OCUL) as of Q3 2025, up from 186 in Q2 2025.
- Funds reported $2.2B of Ocular Therapeutix stock for Q3 2025, up 51% quarter-over-quarter.
- 51 funds opened new Ocular Therapeutix positions in Q3 2025 and 18 closed out, a net change of +33 holders.
- The largest Ocular Therapeutix buyer in Q3 2025 was Fidelity Investments, an estimated $146M added.
- The largest Ocular Therapeutix seller in Q3 2025 was Deep Track Capital, an estimated $28.2M sold.
Based on aggregated 13F filings for Q3 2025.